New combo therapy aims to stop high-risk throat cancer from spreading
NCT ID NCT07248670
First seen Jan 05, 2026 · Last updated May 23, 2026 · Updated 16 times
Summary
This study tests whether adding a low-dose chemotherapy pill (capecitabine) to standard chemoradiotherapy can improve outcomes for people with high-risk nasopharyngeal cancer. It includes 252 adults with stage T1-2N1M0 disease who have certain high-risk features. The goal is to see if the extra treatment helps prevent the cancer from coming back or spreading.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
Conditions
Explore the condition pages connected to this study.